Conference Reports for NATAP

Back

Fourth International Workshop on HIV and Women January 13-14, 2014 Washington DC     Efficacy and Safety of Raltegravir in Women - (01/21/14)   STaR: Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF is Safe and Well-Tolerated with Efficacy Comparable to Efavirenz/Emtricitabine/Tenofovir DF in ART-Naïve Females at Week 96 - (01/21/14)   Raltegravir Efficacy and Safety Similar in Naive Women and Men at 48 Weeks - written by Mark Mascolini (01/16/14)   London Women Lag MSM and Heterosexual Men in Antiretroviral Response and Durability - written by Mark Mascolini (01/16/14)   Response Rates With Complera Versus Atripla in Women at 96 Weeks in STaR - written by Mark Mascolini (01/15/14)   Immune Response to HPV Vaccine Lower in Girls With Than Without HIV - written by Mark Mascolini (01/15/14)   Clinical Characteristics and Quality of HIV Care for Women in the United States: Data from the Medical Monitoring Project, 2009 - written by Mark Mascolini (01/15/14)   Age, Lower CD4s, Winter Predict Missed Clinic Visits by HIV+ Toronto Women - written by Mark Mascolini (01/14/14)   US Women With HIV Get Too Little Support on STIs and HIV Transmission, CDC Says - written by Mark Mascolini (01/14/14)